Kamada is a plasma-derived protein therapeutics company with a commercial product portfolio and a late-stage clinical pipeline. The company uses its proprietary platform technology and expertise for the extraction and purification of proteins from human plasma. The company has two FDA-approved products: GLASSIA, intravenous plasma-derived Alpha-1 Antitrypsin (AAT) for the treatment of AAT deficiency, marketed in the United States through a strategic partnership with Shire Plc; and KEDRAB, a rabies immune globulin (human) product distributed in the United States by Kedrion. Kamada also sells an additional four plasma-derived pharmaceutical products in approximately 20 markets. Kamada has products in late-stage clinical development, including an inhaled formulation of AAT and intravenous AAT for the treatment of type 1 diabetes and GvHD and the prevention of lung transplant rejection.